Shares Climb Over 13% as Tyvaso Meets Primary Endpoint
United Therapeutics (NASDAQ:UTHR) stock increased more than 13% on March 30, 2026, after the company revealed positive topline results from its Phase 3 TETON-1 trial. The study evaluated its inhaled therapy, Tyvaso, for treating idiopathic pulmonary fibrosis (IPF), a severe and progressive lung disease. The trial successfully met its primary endpoint, showing a statistically significant improvement in forced vital capacity (FVC) of 130.1 milliliters at 52 weeks compared to a placebo. Analysts at Jefferies described the outcome as “highly clinically meaningful,” highlighting the drug's potential to alter the course of the debilitating disease.
Data Paves Clear Path for FDA Submission in H2 2026
The positive TETON-1 results are a critical step forward, as this trial serves as a confirmatory study for Tyvaso's efficacy in IPF. This success builds on previously announced positive data from the companion TETON-2 study, which was published in The New England Journal of Medicine. With two successful Phase 3 trials, United Therapeutics has a robust data package to support a regulatory filing. The company confirmed it plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026, seeking to expand Tyvaso's approved uses to include IPF.
Tyvaso Positioned as Potential First Inhaled IPF Therapy
Securing approval for IPF would represent a major commercial opportunity for United Therapeutics. IPF currently has limited treatment options, and Tyvaso is positioned to become the first and only inhaled anti-fibrotic therapy for the condition. Tyvaso, a prostacyclin analogue, is already approved for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). An approval in IPF would significantly broaden its market, offering a new treatment modality for patients, many of whom are already on background antifibrotic therapies. The drug's success distinguishes it within a competitive pipeline of therapies targeting various forms of lung fibrosis.
